Pediatric Cinnarizine Overdose and Toxicokinetics

  title={Pediatric Cinnarizine Overdose and Toxicokinetics},
  author={Dan Turner and Yael Lurie and Yoram Finkelstein and Tal Schmid and Asher Gopher and David M Kleid and Yedidia Bentur},
  pages={e1067 - e1069}
Cinnarizine, a piperazine derivative, is a widely prescribed medication for the treatment of vestibular disorders and motion sickness. Cinnarizine has antihistaminic, antiserotoninergic, antidopaminergic, and calcium channel–blocking properties. We present the first report in the English literature of cinnarizine poisoning and toxicokinetics. A 30-month-old toddler ingested 225 mg of cinnarizine, 18 times the recommended dose for older children. Four hours later, she became jittery with a wide… 

Figures from this paper

Cinnarizine- and flunarizine-associated movement disorder: a literature review
  • J. RissardoA. Caprara
  • Medicine, Psychology
    The Egyptian Journal of Neurology, Psychiatry and Neurosurgery
  • 2020
Parkinsonism was the most well described MD and myoclonus was the poorest described MD with missing data about the neurological examination and electrodiagnostic studies.
Efficacy and safety of cinnarizine in the prophylaxis of migraine headaches in children: an open, randomized comparative trial with propranolol
In this open study, cinnarizine appeared as effective as propranolol and safe for the prophylaxis of migraine in children, but this remains to be confirmed in a double-blind placebo-controlled trial.
Breastfeeding and migraine drugs
A review of the most common anti-migraine drugs and their lactation risk in breastfeeding women found the majority of the revised AMDs to be compatible with breastfeeding.
Recent Advances in Delivery Systems and Therapeutics of Cinnarizine: A Poorly Water Soluble Drug with Absorption Window in Stomach
The paper provides insight to the approaches to overcome low and erratic bioavailability of cinnarizine by cyclodextrin complexes and novel dosage forms: self-nanoemulsifying systems and buoyant microparticulates.
Development and characterization of floating microballoons for oral delivery of cinnarizine by a factorial design
The type of Eudragit used seems to play an important role in producing sustained release floating microspheres in CN by diffusion solvent evaporation technique to increase drug solubility and hence its bioavailability.
Lyophilization-free proliposomes for sustained release oral delivery of hydrophobic drug (cinnarazine): a comparative study
Proliposomes provided a successful approach to deliver lipophilic drugs orally to improve their pharmacokinetic properties by converting their crystalline nature into more amorphous agents.
Design and optimization of gastro-retentive microballoons for enhanced bioavailability of cinnarizine
Results proved the superiority of the designed formulation over the market product Stuval® tablets in bioavailability parameters comprising Tmax as well as area under the plasma CIN concentration-time curve (AUC0–24 h) and AUC0-∞ values.
ADLİ TIP BÜLTENİ The Bullet in of Legal Medicine
This study aimed to investigate the prevalence of psychological and social problems faced by female victims after rape and additionally the impact of also being a victim of childhood sexual abuse in


Cholestasis associated with cinnarizine.
After five days her condition began to improve, and after a further two weeks her renal function and coagulation had returned to normal and epidermal regeneration was complete, and the possibility of this side effect should be borne in mind.
Central effects of cinnarizine: restricted use in aircrew.
Cinnarizine is not free of central activity over the usual therapeutic dose range of 15 to 30 mg, and is contraindicated for motion sickness in aircrew involved in the control of aircraft.
Pharmacokinetics of cinnarizine after single and multiple dosing in healthy volunteers.
Results indicate that cinnarizine accumulates with repetitive dosing due to its pharmacokinetic properties.
Dose-dependent toxicity of diphenhydramine overdose
These data demonstrate a clear dose-dependent acute toxicity of DPHM and indicate that only patients with D PHM ingestions above 1.0 g are at risk for the development of severe symptoms and, therefore, should be hospitalized.
Flunarizine‐ and cinnarizine‐induced extrapyramidal reactions
CinnarIZine and flunarizine must be added to the list of potentially risky drugs known to induce extrapyramidal reactions and depression.
Aggravation of Parkinson's disease by cinnarizine.
A significant worsening of mobility was observed in patients treated with cinnarizine (75 mg bd), whilst no change was recorded in patients receiving placebo in a randomised double-blind parallel study of 20 patients.
Infantile spasms associated with a histamine H1 antagonist.
2 cases of 4-month-old boys who developed infantile spasms 8 to 10 days after ketotifen administration suggest that the administration of ketotIFen to young infants may be hazardous with regard to inducing infantileSpasms.
Effects of calcium antagonists on the dopamine system.
The finding of dopamine-regulating properties not associated to neurotoxic effects in the dihydropyridines and verapamil provides new putative therapeutics tools for the treatment of neurologic disorders associated with dopamine hyperactivity.
Plasma cinnarizine levels resulting from oral administration as capsule or tablet formulation investigated by gas-liquid chromatography.
A gas chromatographic assay for the estimation of therapeutic concentrations of cinnarizine in plasma is described, and no difference was found in the plasma levels or absorption from these formulations.
Classification of calcium antagonists.
  • T. Godfraind
  • Biology, Medicine
    The American journal of cardiology
  • 1987